London Daily

Focus on the big picture.
Thursday, Sep 11, 2025

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

Preliminary results raise hope of fundamental change in cancer treatment.

The technology that saved the day during the COVID-19 pandemic is on the cusp of doing the same for cancer.

Preliminary results from Moderna's ongoing trial of a personalized mRNA cancer vaccine given alongside an immunotherapy from MSD showed a “statistically significant and clinically meaningful reduction in the risk of disease recurrence or death,” the company said Tuesday.

The positive results from the phase 2b trial that tested the vaccine's efficacy and safety paves the way for the final stage of research and then potentially a future approval for the first mRNA cancer vaccine.

Moderna became a household name during the pandemic when its mRNA vaccine became one of two vaccines of choice for many countries. But while the company was delivering hundreds of millions of COVID-19 vaccines around the world, it was also working on trials of its pipeline of different types of cancer vaccines, including one that targets specific gene mutations.

Leading the pack is the company's personalized cancer vaccine. The vaccine, which is being delivered alongside MSD’s immunotherapy Keytruda, is meant to stimulate an immune response based on a patient’s specific tumor. Keytruda then helps the patient’s immune cells to more effectively fight the cancer. The hope was that by working together, the vaccine and the immunotherapy would be able to “bring the power of the immune system to bear on the cancer and to kill it,” said Moderna’s Chief Medical Officer Paul Burton in an interview with POLITICO.

While the current trial is testing the vaccine for melanoma, Moderna is planning additional studies to test it on other cancers. Speaking before the results were released, Burton said that if the trial succeeded it would “be a new paradigm shift, [a] foundational shift that we haven't seen for at least a decade, in a new therapeutic approach for cancer.”

Those hopes appear to have been realized. Preliminary results released today of the trial of 157 melanoma patients indicate that the risk of recurrence of cancer or death was 44 percent lower in those receiving both the vaccine and Keytruda compared to those receiving the immunotherapy alone. The next step is to publish the full data set and start discussions with regulators. Moderna and MSD plan to begin the larger phase 3 trial, which will test effectiveness in more people, in 2023 and “rapidly expand to additional tumor types.”

Cancer is the next major target for mRNA jabs, with companies like Moderna and BioNTech working to prove that their jabs can both outperform existing immunotherapies delivered on their own and provide value to cash-strapped health systems.


Cancer as a chronic disease


What makes the mRNA technology unique is that it can bring together 20 to 30 antigens — substances that trigger an immune response in the body. That's something that's fundamental to the potential success of the vaccine, as it means the immune system is shown a whole range of antigens that the tumor is expressing. “I can’t imagine how you can do that with any other technology,” said Burton.

Unlike Moderna’s COVID-19 vaccine which is “off the shelf” and not tailored to each individual patient, Moderna's personalized cancer vaccine is “supremely complex,” said Burton as “it’s really making a medicine for each individual person.”

The aim? For certain patients in the earlier stage of their disease, the hope is the treatment could potentially prevent the disease from progressing. In patients with more advanced disease, the desire is to extend their life, with their cancer becoming something of a chronic disease.

“We would hope that if we can really prove this, that it will be a fundamental shift in the way that — at least for certain kinds of cancer — we treat them and the clinical benefit could really be profound,” said Burton.

The other factor is side effects. Or rather, the relative lack of them compared to, say, chemotherapy drugs. “If you can get real clinical benefit with a really manageable safety profile, I really think could be transformational," said the chief medical officer. The topline results on Tuesday indicate that the adverse events were consistent with those reported in the phase 1 trial, which found the vaccine had an acceptable safety profile.

One of the major obstacles with immunotherapies is the price. There’s concern that the same will happen with mRNA cancer vaccines. While these kinds of decisions are some way off, it’s a concern that Sam Godfrey, senior research information manager at Cancer Research U.K. (CRUK), previously expressed concern about.

“If something's costing a million pounds per treatment for a personalized vaccine, and its effectiveness isn't much better than standard chemotherapy, which doesn't cost very much, you've got that decision about, actually, is this worth investing in?” said Godfrey earlier this year.

Moderna’s Burton said he had not yet been in discussions around price. But he argued that mRNA has “huge potential” to bring value to many people around the world. “We want to bring equitable health care to people all around the world,” he said. “So we want to work with governments and with payers to do that, but I think it's premature yet to really think about price.”

Comments

Oh ya 3 year ago
If anyone takes a shot for anything after what has come out about the covid19 shot you deserve the blood clots and sudden death syndrome. You failed one world IQ test don't fail another

Newsletter

Related Articles

0:00
0:00
Close
ChatGPT CEO signals policy to alert authorities over suicidal youth after teen’s death
The British legal mafia hit back: Banksy mural of judge beating protester is scrubbed from London court
Surpassing Musk: Larry Ellison becomes the richest man in the world
Embarrassment for Starmer: He fired the ambassador photographed on Epstein’s 'pedophile island'
Manhunt after 'skilled sniper' shot Charlie Kirk. Footage: Suspect running on rooftop during panic
Effective Protest Results: Nepal’s Prime Minister Resigns as Youth-Led Unrest Shakes the Nation
Qatari prime minister says Netanyahu ‘killed any hope’ for Israeli hostages
King Charles and Prince Harry Share First In-Person Moment in 19 Months
Starmer Establishes Economic ‘Budget Board’ to Centralise Policy and Rebuild Business Trust
France Erupts in Mass ‘Block Everything’ Protests on New PM’s First Day
Poland Shoots Down Russian Drones in Airspace Violation During Ukraine Attack
Brazilian police say ex-President Bolsonaro had planned to flee to Argentina seeking asylum
Trinidad Leader Applauds U.S. Naval Strike and Advocates Forceful Action Against Traffickers
Kim Jong Un Oversees Final Test of New High-Thrust Solid-Fuel Rocket Engine
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Macron Appoints Sébastien Lecornu as Prime Minister Amid Budget Crisis and Political Turmoil
Supreme Court temporarily allows Trump to pause billions in foreign aid
Charlie Sheen says his father, Martin Sheen, turned him in to the police: 'The greatest betrayal possible'
Vatican hosts first Catholic LGBTQ pilgrimage
Apple Unveils iPhone 17 Series, iPhone Air, Apple Watch 11 and More at 'Awe Dropping' Event
Pig Heads Left Outside Multiple Paris Mosques in Outrage-Inducing Acts
Nvidia’s ‘Wow’ Factor Is Fading. The AI chip giant used to beat Wall Street expectations for earnings by a substantial margin. That trajectory is coming down to earth.
France joins Eurozone’s ‘periphery’ as turmoil deepens, say investors
On the Anniversary of Queen Elizabeth’s Death: Prince Harry Returns to Britain
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Murdoch Family Finalises $3.3 Billion Succession Pact, Ensuring Eldest Son’s Leadership
Big Oil Slashes Jobs and Investments Amid Prolonged Low Crude Prices
Court Staff Cover Up Banksy Image of Judge Beating a Protester
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
Elon Musk Poised to Become First Trillionaire Under Ambitious Tesla Pay Plan
France, at an Impasse, Heads Toward Another Government Collapse
Burning the Minister’s House Helped Protesters to Win Justice: Prabowo Fires Finance Minister in Wake of Indonesia Protests
Brazil Braces for Fallout from Bolsonaro Trial by corrupted judge
The Country That Got Too Rich? Public Spending Dominates Norway Election
Nearly 40 Years Later: Nike Changes the Legendary Slogan Just Do It
Generations Born After 1939 Unlikely to Reach Age One Hundred, New Study Finds
End to a four-year manhunt in New Zealand: the father who abducted his children to the forests was killed, the three siblings were found
Germany Suspends Debt Rules, Funnels €500 Billion Toward Military and Proxy War Strategy
EU Prepares for War
BMW Eyes Growth in China with New All‑Electric Neue Klasse Lineup
Trump Threatens Retaliatory Tariffs After EU Imposes €2.95 Billion Fine on Google
Tesla Board Proposes Unprecedented One-Trillion-Dollar Performance Package for Elon Musk
US Justice Department Launches Criminal Mortgage-Fraud Probe into Federal Reserve Governor Lisa Cook
Escalating Drug Trafficking and Violence in Latin America: A Growing Crisis
US and Taiwanese Defence Officials Held Secret Talks in Alaska
Report: Secret SEAL Team 6 Mission in North Korea Ordered by Trump in 2019 Ended in Failure
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Florida Murder Case: The Adelson Family, the Killing of Dan Markel, and the Trial of Donna Adelson
×